Steve Wedge

Professor Steve Wedge is a cancer pharmacologist who has specialised in oncology drug discovery and development for over 35 years. He is a contributor to the discovery of 12 candidate oncology drugs, including the first targeted therapy to gain regulatory approval for the treatment of advanced medullary thyroid cancer.  

He has experience of working across all drug discovery phases; from target selection and validation, lead identification and optimisation, through to translational science and early clinical development.  

Steve worked at AstraZeneca for 16 years before becoming Professor of Stratified Cancer Medicine Discovery at Newcastle University in 2012. He has been Chief Scientific Officer for Cancer Research Horizons Therapeutic Innovation since 2022.